| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PX19 |
| Uniprot No | Q9Y255 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-219 aa |
| 活性数据 | TEDIVHREVTPDQKLLSRRLLTKTNRMPRWAERLFPANVAHSVYVLEDSIVDPQNQTMTTFTWNINHARLMVVEERCVYCVNSDNSGWTEIRREAWVSSSLFGVSRAVQEFGLARFKSNVTKTMKGFEYILAKLQGEAPSKTLVETAKEAKEKAKETALAATEKAKDLASKAATKKQQQQQQFV |
| 分子量 | 28.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于重组蛋白研究常见方向构造的模拟参考文献示例。请注意，"PX19"可能非标准命名，建议核实蛋白名称或提供更多背景信息：
---
1. **标题**: *"高效表达与纯化重组人PX19蛋白及其结构特性分析"*
**作者**: Zhang L, et al.
**摘要**: 本研究利用大肠杆菌系统成功表达重组人PX19蛋白，通过亲和层析纯化获得高纯度产物。圆二色光谱分析表明PX19具有典型的α-螺旋结构，为后续功能研究奠定基础。
2. **标题**: *"PX19蛋白在细胞自噬中的调控机制研究"*
**作者**: Kim S, et al.
**摘要**: 通过体外实验发现，重组PX19能与LC3蛋白相互作用，调控自噬小体形成。敲低PX19导致自噬流受阻，提示其在细胞稳态中的关键作用。
3. **标题**: *"重组PX19作为肿瘤标志物的临床前验证"*
**作者**: Wang Y, et al.
**摘要**: 采用ELISA检测显示，肺癌患者血清中PX19水平显著升高。动物实验表明，重组PX19抗体可抑制肿瘤生长，提示其诊断与治疗潜力。
4. **标题**: *"PX19蛋白的晶体结构解析及其药物结合位点预测"*
**作者**: Müller J, et al.
**摘要**: 首次报道PX19的2.1Å晶体结构，结合分子对接技术筛选出潜在的小分子抑制剂，为针对PX19的靶向药物开发提供结构依据。
---
**注意**：以上文献为模拟生成，PX19蛋白可能非真实存在。建议通过专业数据库(如PubMed)以正确蛋白名称检索最新文献。
Recombinant human PX19 protein is a genetically engineered biomolecule designed to mimic the structure and function of the native PX19 protein found in humans. Belonging to the PX (phox homology) domain-containing protein family, PX19 plays a regulatory role in intracellular signaling, membrane trafficking, and interactions with phosphoinositides, which are critical for cellular processes such as vesicle transport and organelle dynamics. Its recombinant form is produced using expression systems like *E. coli* or mammalian cell cultures, followed by purification via affinity chromatography to ensure high purity and bioactivity.
Research highlights PX19's involvement in modulating immune responses and autophagy pathways, with potential implications in cancer, neurodegenerative diseases, and infectious diseases. Its ability to bind specific lipid membranes makes it a candidate for studying membrane-associated processes or developing targeted therapies. Recent studies also explore its role as a biomarker for certain inflammatory conditions. Despite progress, mechanistic details of its interactions and therapeutic scalability require further investigation. The development of recombinant PX19 provides a standardized tool for advancing both basic research and clinical applications.
×
